BRAF-Mutant Metastatic Colorectal Cancer: Current Evidence, Future Directions, and Research Priorities
Clinical Colorectal Cancer · 2024
DOI: 10.1016/j.clcc.2024.04.004 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Colorectal Cancer, 2024. Verfasst von Oliver Piercey und 5 weiteren Autor:innen. Beteiligte Einrichtung: Peter MacCallum Cancer Centre, Melbourne, Australia; Centre for Cancer Research, The University of Melbourne, Melbourne, Australia; Department of Cli…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Colorectal Neoplasms, Mutation, Molecular Targeted Therapy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 122 Literaturangaben.
Abstract (Originalsprache)
BRAFV600E-mutant metastatic colorectal cancer represents a distinct molecular phenotype known for its aggressive biological behavior, resistance to standard therapies, and poor survival rates. Improved understanding of the biology of the BRAF oncogene has led to the development of targeted therapies that have paved the way for a paradigm shift in managing this disease. However, despite significant recent advancements, responses to targeted therapies are short-lived, and several challenges remain. In this review, we discuss how progress in treating BRAFV600E-mutant metastatic colorectal cancer has been made through a better understanding of its unique biological and clinical features. We provide an overview of the evidence to support current treatment approaches and discuss critical areas of need and future research strategies that hold the potential to refine clinical practice further. We also discuss some challenging aspects of managing this disease, particularly the complexity of acquired resistance mechanisms that develop under the selective pressure of targeted therapies and rational strategies being investigated to overcome them.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peter MacCallum Cancer Centre, Melbourne, Australia; Centre for Cancer Research, The University of Melbourne, Melbourne, Australia; Department of Clinical Pathology, The University of Melbourne, Australia. Electronic ad…
- Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia; Walter and Eliza Hall Institute of Medical Research, Parkville, Austral…
- Centre for Cancer Research, The University of Melbourne, Melbourne, Australia; Department of Clinical Pathology, The University of Melbourne, Australia.
- Olivia Newton John Cancer Wellness and Research Centre, Heidelberg, Australia; School of Medicine, La Trobe University, Melbourne, Australia.
- Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia.
Zitieren
APA
Piercey, O., Tie, J., Hollande, F., Wong, H. L., Mariadason, J., & Desai, J. (2024). BRAF-Mutant Metastatic Colorectal Cancer: Current Evidence, Future Directions, and Research Priorities. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2024.04.004
Vancouver
Piercey O, Tie J, Hollande F, Wong HL, Mariadason J, Desai J. BRAF-Mutant Metastatic Colorectal Cancer: Current Evidence, Future Directions, and Research Priorities. Clinical Colorectal Cancer. 2024. doi:10.1016/j.clcc.2024.04.004
BibTeX
@article{Piercey2024,
author = {Piercey, Oliver and Tie, Jeanne and Hollande, Frederic and Wong, Hui-Li and Mariadason, John and Desai, Jayesh},
title = {BRAF-Mutant Metastatic Colorectal Cancer: Current Evidence, Future Directions, and Research Priorities},
journal = {Clinical Colorectal Cancer},
year = {2024},
doi = {10.1016/j.clcc.2024.04.004}
}
EUVIMED